Jakarta, November 8, 2018 - PT Kalbe Farma Tbk. (Kalbe) today commenced the signing of a Memorandum of Understanding with the Executive Board of the Indonesian Doctors' Association (IDI) to support and participate in the commencement of the Research Institute that is established by PB IDI of the 2018-2021 period. Kalbe plans to support the research institute's activities, among which will include the collaboration in developing research journals, awarding proposals and the best health research results for doctors in Indonesia as well as supporting other research programs. The memorandum of understanding to support of the IDI research institute's activities was signed by Dr. Michael Bujung Nugroho, Director of PT Kalbe Farma Tbk and Dr. Daeng M Faqih, SH, MH, General Chairman of IDI's Executive Board.
"Kalbe welcomes and supports the formation of the Indonesian Doctors Association's research institute," said Dr. Michael Bujung Nugroho, Director of PT Kalbe Farma Tbk, "Through the collaboration with IDI we hope that Kalbe can contribute significantly in enriching researches in the Health sector, while strengthening collaboration between Academics, Business and Government," he continued.
"At present, the technology of health services and medicine is experiencing advancement and are being encouraged to compete. Therefore IDI felt the need to form a research institute in order to develop the research fields in the medical world." Said Dr. Daeng M Faqih, SH, MH, General Chairman of IDI's Executive Board of the 2018-2021 period. "We realize that we cannot do it alone and will have to collaborate, one of it is to collaborate with Kalbe," he added.
"Through this research institute, IDI will provide new colors in the development of research in the country,"added Dr. Marhaen Hardjo M Biomed PhD, Chairman of the IDI Research Institute. The scopes of research of the Institute are, among others, related to the medical services as well as providing support for clinical decisions.
The research institute that was established alongside the inauguration of the Executive Board of the Indonesian Doctors' Association has the purposes of, among which, improving the competence of medical services, chasing Indonesia's lack of technological mastery, improving innovations of the medical services, increase competitiveness and improve the dignity of Indonesian physicians, as well as utilizing the research results as bases of policy making of the health sector. The IDI research institute also has the vision to become a leading research institute toward the Industry 4.0 era, with the missions of Convergent Thinking, Big Data, Precision Medicine.
Aside of the support for IDI's research institute, Kalbe is also collaborating with the Ministry of Research, Technology, and Higher Education to provide research grants in Indonesia through the Ristekdikti-Kalbe Science Awards program. The research grant is directed toward researches that have the readiness to be commercialized; therefore the research results can be enjoyed by the general public.
Through its subsidiary, PT Hexpharm Jaya, Kalbe also hosts the HJ Learning Forum that aims to provide knowledge and insights to physicians in order to understand clinic management, specifically first-level clinics, in order for it to be able to support the government program, JKN. This activity has been conducted at numerous cities in Indonesia.
Kalbe at a glance
PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); over-the-counter medication division (Woods, Promag, Mixagrip, Komix, Fatigon, etc.); health drinks (Hydro Coco, Extra Joss, Nitros); nutrition division (ChilKid, Prenagen, Diabetasol, etc.); and distribution division. Kalbe currently has more than 35 subsidiaries, 14 production facilities with international standard, and employs more than 17,000 employees dispersed across more than 72 branches throughout Indonesia. From 1991, Kalbe is listed at Indonesia Stock Exchange (IDX: KLBF).
PT Hexpharm Jaya at a glance
PT. Hexpharm Jaya Laboratories, established in 1971, runs with the specialization in the development, production, and marketing of generic drugs. PT Jaya Hexpharm Laboratories is committed in prioritizing the quality of drugs produced, to ensure their effectiveness, stability and safety. PT. Hexpharm Jaya Laboratories, a subsidiary of PT. Kalbe Farma Tbk, is listed as one of the 20 largest pharmaceutical companies (ethical) in Indonesia as well as being one of the 3 largest generic pharmaceutical companies in Indonesia.